Cargando…

Immune cell profiles of metastatic HER2-positive breast cancer patients according to the sites of metastasis

PURPOSE: Recent works have characterized that metastatic site can affect the tumour immune profiles and efficiency of cancer immunotherapies. The prognosis of HER2-positive breast cancer is associated with the characteristics of the tumour immune microenvironment, with immunological cells playing a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Honkanen, Tiia J., Luukkainen, Milla E. K., Tikkanen, Antti, Karihtala, Peeter, Mäkinen, Markus, Väyrynen, Juha P., Koivunen, Jussi P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2021
Materias:	Epidemiology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8763933/ https://www.ncbi.nlm.nih.gov/pubmed/34817749 http://dx.doi.org/10.1007/s10549-021-06447-6

Ejemplares similares

Prognostic and predictive role of tumour-associated macrophages in HER2 positive breast cancer
por: Honkanen, Tiia J., et al.
Publicado: (2019)

Prognostic and predictive role of spatially positioned tumour infiltrating lymphocytes in metastatic HER2 positive breast cancer treated with trastuzumab
por: Honkanen, Tiia J., et al.
Publicado: (2017)

Retrospective analysis of HER2 therapy interruption in patients responding to the treatment in metastatic HER2+ breast cancer
por: Moilanen, Tiina, et al.
Publicado: (2017)

Role of human epidermal growth factor receptor 3 in treatment resistance of anaplastic lymphoma kinase translocated non-small cell lung cancer
por: Honkanen, Tiia J, et al.
Publicado: (2023)

Treatment discontinuation and re-initiation of anti-PD-(L)1 agents in metastatic cancers
por: Tikkanen, Antti, et al.
Publicado: (2020)

Long-term survivor characteristics in HER2-positive metastatic breast cancer from registHER
por: Yardley, D A, et al.
Publicado: (2014)

Real-world treatment in patients with HER2+ metastatic breast cancer: Treatment decisions in HER2+ mBC
por: Colomer, R., et al.
Publicado: (2017)

Predictors of successful neoadjuvant treatment in HER2‑positive breast cancer
por: Hännikäinen, Elli-Noora, et al.
Publicado: (2023)

Association of antidiabetic medication and statins with breast cancer incidence in women with type 2 diabetes
por: Hosio, Mayu, et al.
Publicado: (2019)

Treatment patterns and clinical outcomes in elderly patients with HER2-positive metastatic breast cancer from the registHER observational study
por: Kaufman, Peter A., et al.
Publicado: (2012)

Time-dependent risk of developing distant metastasis in breast cancer patients according to treatment, age and tumour characteristics
por: Colzani, E, et al.
Publicado: (2014)

Racial disparities in treatment patterns and clinical outcomes in patients with HER2-positive metastatic breast cancer
por: Rugo, Hope S., et al.
Publicado: (2013)

Trastuzumab therapy duration in HER2-positive de novo metastatic breast cancer: 1999–2018
por: Kaplan, Henry G., et al.
Publicado: (2022)

High Parity Predicts Poor Outcomes in Patients With Luminal B-Like (HER2 Negative) Early Breast Cancer: A Prospective Finnish Single-Center Study
por: Jääskeläinen, Anniina, et al.
Publicado: (2020)

Cardiotoxicity during long-term trastuzumab use in patients with HER2-positive metastatic breast cancer: who needs cardiac monitoring?
por: Bouwer, N. I., et al.
Publicado: (2021)

Treatment patterns and clinical outcomes for patients with de novo versus recurrent HER2-positive metastatic breast cancer
por: Yardley, Denise A., et al.
Publicado: (2014)

Angiogenesis Inhibitors for Head and Neck Squamous Cell Carcinoma Treatment: Is There Still Hope?
por: Hyytiäinen, Aini, et al.
Publicado: (2021)

Prognostic factors in metastatic breast cancer: a prospective single-centre cohort study in a Finnish University Hospital
por: Karihtala, Peeter, et al.
Publicado: (2020)

Salt intake and gastric cancer risk according to Helicobacter pylori infection, smoking, tumour site and histological type
por: Peleteiro, B, et al.
Publicado: (2011)

The mutational signatures of cancer: can passengers set a direction for prognosis?
por: Karihtala, Peeter
Publicado: (2023)

Role of hormonal risk factors in HER2-positive breast carcinomas
por: Balsari, A, et al.
Publicado: (2003)

Delay in initiation of adjuvant trastuzumab therapy leads to decreased overall survival and relapse-free survival in patients with HER2-positive non-metastatic breast cancer
por: Gallagher, Christopher M., et al.
Publicado: (2016)

Epidemiology of interstitial lung disease in patients with metastatic breast cancer at baseline and after treatment with HER2-directed therapy: a real-world data analysis
por: Law, Jeanna Wallenta, et al.
Publicado: (2022)

Systemic inflammation in colorectal cancer: Underlying factors, effects, and prognostic significance
por: Tuomisto, Anne E, et al.
Publicado: (2019)

Diagnostic value of core needle biopsy for determining HER2 status in breast cancer, especially in the HER2-low population
por: Chen, Ruixian, et al.
Publicado: (2022)

Survival outcomes for Australian women receiving trastuzumab for HER2-positive metastatic breast cancer following (neo)adjuvant trastuzumab: a national population-based observational study (2006–2014)
por: Daniels, Benjamin, et al.
Publicado: (2018)

Indoleamine 2,3-dioxygenase expression in patients with allergic rhinitis: a case-control study
por: Luukkainen, Annika, et al.
Publicado: (2011)

Integrin alpha 10, CD44, PTEN, cadherin-11 and lactoferrin expressions are potential biomarkers for selecting patients in need of central nervous system prophylaxis in diffuse large B-cell lymphoma
por: Lemma, Siria A, et al.
Publicado: (2017)

The prognostic and predictive roles of plasma C‐reactive protein and PD‐L1 in non‐small cell lung cancer
por: Kuusisalo, Saara, et al.
Publicado: (2023)

Are we able to predict survival in ER-positive HER2-negative breast cancer? A comparison of web-based models
por: Laas, E, et al.
Publicado: (2015)

Cervical cancer mortality in Norway according to screening attendance and age
por: Baasland, Ingrid, et al.
Publicado: (2022)

A prognostic score based on B cell and plasma cell densities compared to T cell densities in colorectal cancer
por: Karjalainen, Henna, et al.
Publicado: (2023)

Clinical impact and network of determinants of tumour necrosis in colorectal cancer
por: Väyrynen, Sara A, et al.
Publicado: (2016)

Concurrent versus sequential use of trastuzumab and chemotherapy in early HER2+ breast cancer
por: Dackus, Gwen M. H. E., et al.
Publicado: (2020)

Mutational signatures and their association with survival and gene expression in urological carcinomas
por: Karihtala, Peeter, et al.
Publicado: (2023)

Estimation of the probability of daily fluctuations of incidence of COVID-19 according to official data
por: Gerasimov, Andrey, et al.
Publicado: (2021)

Survival before and after the introduction of pertuzumab and T-DM1 in HER2-positive advanced breast cancer, a study of the SONABRE Registry
por: Ibragimova, Khava I. E., et al.
Publicado: (2021)

Impact of alcohol drinking on gastric cancer development according to Helicobacter pylori infection status
por: Ma, Seung-Hyun, et al.
Publicado: (2015)

Outcomes for the first four lines of therapy in patients with HER2-positive advanced breast cancer: results from the SONABRE registry
por: Ibragimova, Khava I. E., et al.
Publicado: (2023)

Triple-negative and HER2-positive breast cancers found by mammography screening show excellent prognosis
por: Alanko, Johanna, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_0nkqau1h9g8qf81sa2cmirivdt